Amyloid-targeted antibodies seem to have a small clinical benefit in patients with mild Alzheimer disease, but concerns about the design and interpretation of the trials curb enthusiasm.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
MicroRNA-298 reduces levels of human amyloid-β precursor protein (APP), β-site APP-converting enzyme 1 (BACE1) and specific tau protein moieties
Molecular Psychiatry Open Access 15 January 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
05 October 2015
The description of the reanalysis of the EXPEDITION 1, 2 and EXT trials of solanezumab on p592 was inaccurate, and it is the last patient visit for the EXPEDITION 3 trial that is due in October 2016, not the final results. Changes have been made to correct these errors in the online version of the article.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Reardon, S. Alzheimer antibody drugs show questionable potential. Nat Rev Drug Discov 14, 591–592 (2015). https://doi.org/10.1038/nrd4709
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4709
This article is cited by
-
MicroRNA-298 reduces levels of human amyloid-β precursor protein (APP), β-site APP-converting enzyme 1 (BACE1) and specific tau protein moieties
Molecular Psychiatry (2021)
-
Erratum: Alzheimer antibody drugs show questionable potential
Nature Reviews Drug Discovery (2015)
